

One Year Follow-up of the Melody™ Transcatheter Pulmonary Valve Multicenter Post-Approval Study

Aimee K. Armstrong, MD¹, David Balzer, MD², Allison Cabalka³, MD, Robert Gray, MD⁴, Alexander Javois, MD⁵, Jacqueline Kreutzer, MD⁶, John Moore, MD⁷, Jonathan Rome, MD⁸, Daniel Turner, MD⁹, Thomas Zellers, MD¹⁰

¹University of Michigan, ²St. Louis Children's Hospital, ³Mayo Clinic Rochester, ⁴University of Utah, ⁵Hope Children's Hospital, ⁶University of Pittsburgh Medical Center, ⁷Rady Children's Hospital, ⁸Children's Hospital of Philadelphia, ⁹Children's Hospital of Michigan, ¹⁰Children's Medical Center Dallas

Disclosures

Aimee K. Armstrong, MD

- Medtronic: Research/Research Grants
- Edwards Lifesciences: Research/Research Grants
- Siemens Healthcare AX: Consultant Fees/Honoraria
- St. Jude Medical: Consultant Fees/Honoraria


Disclosures

Melody™ Transcatheter Pulmonary Valve (TPV) is approved as a Humanitarian Use Device.


Authorized by Federal law (USA) for use in pediatric and adult patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit (≥ 16 mm in diameter when originally implanted).

The effectiveness of this device for this use has not been demonstrated.


RV-PA Conduits



Congenital Heart Defects




RV-PA Conduit Dysfunction



Melody™ TPV

- Designed to:
 - Delay the time until surgical RV-PA conduit replacement is needed
 - Reduce the total number of open heart surgeries over a patient's lifetime



Melody™ TPV

- Bovine Jugular Vein Valve
- Platinum Iridium Frame
 - Expandable to 18mm, 20mm or 22mm
- Delivered on the Ensemble® Delivery System
 - 22Fr Balloon-in-Balloon (BIB) catheter
- FDA Approval with HDE designation in 2010



Melody TPV Post-Approval Study Objective

- To confirm that short-term hemodynamic effectiveness of the Melody TPV achieved by real-world providers is equivalent to the historical results established in the five-center IDE trial

Endpoints

- Primary Endpoint
 - Acceptable hemodynamic function at 6 months post-implant
 - RVOT echocardiographic mean gradient ≤ 30 mmHg
 - Regurgitation < moderate by echocardiogram
 - Freedom from conduit reintervention and reoperation
- Secondary Endpoints
 - Procedural success
 - Freedom from serious adverse events
 - Freedom from TPV dysfunction


Methods

- Prospective, non-randomized, 10-center study
- Patients with a stenotic and/or regurgitant conduit
 - ≥ 16 mm at implantation
- No weight or age limit
- Planned 5-year follow-up

Baseline Characteristics

<i>Characteristics (N=120)</i>	<i>Mean ± SD</i>
Age (years)	19.9 ± 9.7
Weight (kg)	59.4 ± 21.7
RVOT Mean Gradient (mmHg)	34.6 ± 14.5
Primary Indication (%)	
Stenotic	20.8
Regurgitant	47.5
Mixed	31.7

Subject Disposition




98% Procedural Success:

- Peak cath gradient <35 mmHg
- No more than mild regurgitation


Follow-up: 22 ±18.9 months

Primary Endpoint


6-month Acceptable Hemodynamic Function




One Year Acceptable Hemodynamic Function




RVOT Mean Gradient



Pulmonary Regurgitation




Freedom from TPV Dysfunction, Reoperation, and Reintervention



Number At Risk	0	1	5	7	12
Catheter Reintervention	99	99	98	89	89
Reoperation	99	99	98	89	89
TPV Dysfunction	99	98	96	88	88

Freedom from TPV Dysfunction, Reoperation, and Reintervention



Number At Risk	0	1	5	12
Catheter Reintervention	99	99	98	89
Reoperation	99	99	98	89
TPV Dysfunction	99	98	96	88

Complications

- Serious Adverse Events
 - Procedural: 16 of 120 patients (13.3%)
 - Confined conduit tear (n=6)
 - All resolved with covered stent
 - Vascular complications (n=4)
 - Other adverse events included coronary compression, distal PA perforation, arrhythmia, fever, paravalvular leak, and pulmonary edema
 - In First Year: 8 of 99 implants >24 hours (8.1%)
 - Endocarditis (n=3), 1 with reoperation
 - Sepsis (n=1)
 - Major stent fracture requiring reoperation (n=1)
 - Pulmonary embolism (n=1)
 - Arrhythmia / palpitations (n=2)

Conclusions

- This study confirms the strong performance of the Melody TPV achieved by real-world providers with results comparable to the US IDE trial
 - Excellent hemodynamic function at 6 months (96.7%)
 - High Procedural Success (98.0%)
 - Serious Adverse Events:
 - Procedural: 13.3%
 - First year: 8.1%
 - High freedom from TPV dysfunction at 1 year (96.9%)